Lexicon Genetics Announces Issuance of Two Key Gene Trapping Patents

- Patented Technology for Gene Function Discovery -



Apr 10, 2001, 01:00 ET from Lexicon Genetics Incorporated

    THE WOODLANDS, Texas, April 10 /PRNewswire/ --
 Lexicon Genetics Incorporated (Nasdaq:   LEXG) today announced that it has been
 issued U.S. Patent No. 6,207,371 (the "371 patent") entitled "Indexed Library
 of Cells Containing Genomic Modifications and Methods of Making and Utilizing
 the Same."  The newly-issued patent extends the scope of Lexicon's broad
 patent estate in the field of gene trapping, now covered by a total of four
 issued U.S. patents.  The gene trapping patents complement Lexicon's gene
 targeting patent portfolio to provide the company with broad coverage over
 technologies used to efficiently determine the in vivo functions of genes and
 their pharmaceutical applications.  Lexicon has used its gene trapping
 technology to discover genes having pharmaceutical product potential in the
 areas of cancer, cardiovascular disease, immune disorders, neurological
 disease, diabetes and obesity.
     The 371 patent broadly covers the gene trapping technology that Lexicon
 has used to generate its OmniBank(R) library of well over 100,000 gene
 knockout clones.  Lexicon is using OmniBank to systematically discover the
 functions of genes uncovered by the Human Genome Project and other sequencing
 efforts, determining the medical importance of genes and their value for drug
 discovery and development based on in vivo mammalian biology.  Lexicon has
 recently accelerated its OmniBank production and estimates that the OmniBank
 library now contains gene knockout clones for more than 40% of all genes in
 the mammalian genome.
     The 371 patent also covers the gene trapping technology that Lexicon has
 used to discover gene sequence information from thousands of human genes.
 Lexicon has filed patent applications covering more than 50,000 partial human
 gene sequences from its gene trapping program.
     Finally, the 371 patent covers collections of mutated animal cells such as
 the knockout mouse ES cell clones contained in Lexicon's OmniBank library, as
 well as Lexicon's gene trapping vectors and related methods.  Lexicon also
 announced the earlier issuance of U.S. Patent No. 6,139,833 (the "833 patent")
 entitled "Targeted Gene Discovery."  The 833 patent also covers elements of
 Lexicon's gene trapping technology.
     "These patents further confirm Lexicon's leadership and ownership position
 in technologies for defining mammalian gene function for drug discovery," said
 Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of
 Lexicon.  "We believe that both our genome-wide gene trapping and
 gene-specific gene targeting technologies provide us with unique competitive
 advantages in translating gene discoveries into new therapeutic products."
     Lexicon Genetics Incorporated is a leader in defining the functions of
 genes for drug discovery.  Lexicon uses its patented gene targeting knockout
 technology and its high-throughput genome-wide gene trapping technology to
 discover thousands of genes and expand its OmniBank(R) library of more than
 100,000 knockout clones.  The Company uses an integrated platform of
 functional genomics technologies to accelerate large-scale analysis of
 mammalian gene function for drug discovery.  Through Lexicon's corporate
 website, www.lexicon-genetics.com, researchers worldwide can access the
 OmniBank library and form collaborations with Lexicon to discover
 pharmaceutical products based on genes and knowledge of their functions.
 Lexicon has established drug discovery alliances with major pharmaceutical and
 biotechnology companies as well as leading academic institutions worldwide.
     Statements in this release relating to Lexicon that are not historical
 facts or information are "forward-looking statements" within the meaning of
 the Private Securities Litigation Reform Act of 1995.  Such forward-looking
 statements are based on management's current assumptions and expectations.
 Such forward-looking statements involve risks, uncertainties and other
 important factors, specifically including those relating to Lexicon's ability
 to enforce its patents, that may cause the actual results of Lexicon to be
 materially different from any future results expressed or implied by such
 forward-looking statements, and there can be no assurance that actual results
 will not differ materially from management's expectations.  Information
 identifying such important factors is contained under "Factors Affecting
 Forward-Looking Statements" and "Business -- Risk Factors" in our annual
 report on Form 10-K for the year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  Lexicon undertakes no obligation to
 update any such forward-looking statements.
 
 

SOURCE Lexicon Genetics Incorporated
    THE WOODLANDS, Texas, April 10 /PRNewswire/ --
 Lexicon Genetics Incorporated (Nasdaq:   LEXG) today announced that it has been
 issued U.S. Patent No. 6,207,371 (the "371 patent") entitled "Indexed Library
 of Cells Containing Genomic Modifications and Methods of Making and Utilizing
 the Same."  The newly-issued patent extends the scope of Lexicon's broad
 patent estate in the field of gene trapping, now covered by a total of four
 issued U.S. patents.  The gene trapping patents complement Lexicon's gene
 targeting patent portfolio to provide the company with broad coverage over
 technologies used to efficiently determine the in vivo functions of genes and
 their pharmaceutical applications.  Lexicon has used its gene trapping
 technology to discover genes having pharmaceutical product potential in the
 areas of cancer, cardiovascular disease, immune disorders, neurological
 disease, diabetes and obesity.
     The 371 patent broadly covers the gene trapping technology that Lexicon
 has used to generate its OmniBank(R) library of well over 100,000 gene
 knockout clones.  Lexicon is using OmniBank to systematically discover the
 functions of genes uncovered by the Human Genome Project and other sequencing
 efforts, determining the medical importance of genes and their value for drug
 discovery and development based on in vivo mammalian biology.  Lexicon has
 recently accelerated its OmniBank production and estimates that the OmniBank
 library now contains gene knockout clones for more than 40% of all genes in
 the mammalian genome.
     The 371 patent also covers the gene trapping technology that Lexicon has
 used to discover gene sequence information from thousands of human genes.
 Lexicon has filed patent applications covering more than 50,000 partial human
 gene sequences from its gene trapping program.
     Finally, the 371 patent covers collections of mutated animal cells such as
 the knockout mouse ES cell clones contained in Lexicon's OmniBank library, as
 well as Lexicon's gene trapping vectors and related methods.  Lexicon also
 announced the earlier issuance of U.S. Patent No. 6,139,833 (the "833 patent")
 entitled "Targeted Gene Discovery."  The 833 patent also covers elements of
 Lexicon's gene trapping technology.
     "These patents further confirm Lexicon's leadership and ownership position
 in technologies for defining mammalian gene function for drug discovery," said
 Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of
 Lexicon.  "We believe that both our genome-wide gene trapping and
 gene-specific gene targeting technologies provide us with unique competitive
 advantages in translating gene discoveries into new therapeutic products."
     Lexicon Genetics Incorporated is a leader in defining the functions of
 genes for drug discovery.  Lexicon uses its patented gene targeting knockout
 technology and its high-throughput genome-wide gene trapping technology to
 discover thousands of genes and expand its OmniBank(R) library of more than
 100,000 knockout clones.  The Company uses an integrated platform of
 functional genomics technologies to accelerate large-scale analysis of
 mammalian gene function for drug discovery.  Through Lexicon's corporate
 website, www.lexicon-genetics.com, researchers worldwide can access the
 OmniBank library and form collaborations with Lexicon to discover
 pharmaceutical products based on genes and knowledge of their functions.
 Lexicon has established drug discovery alliances with major pharmaceutical and
 biotechnology companies as well as leading academic institutions worldwide.
     Statements in this release relating to Lexicon that are not historical
 facts or information are "forward-looking statements" within the meaning of
 the Private Securities Litigation Reform Act of 1995.  Such forward-looking
 statements are based on management's current assumptions and expectations.
 Such forward-looking statements involve risks, uncertainties and other
 important factors, specifically including those relating to Lexicon's ability
 to enforce its patents, that may cause the actual results of Lexicon to be
 materially different from any future results expressed or implied by such
 forward-looking statements, and there can be no assurance that actual results
 will not differ materially from management's expectations.  Information
 identifying such important factors is contained under "Factors Affecting
 Forward-Looking Statements" and "Business -- Risk Factors" in our annual
 report on Form 10-K for the year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  Lexicon undertakes no obligation to
 update any such forward-looking statements.
 
 SOURCE  Lexicon Genetics Incorporated